Last reviewed · How we verify
HDV-Lispro
At a glance
| Generic name | HDV-Lispro |
|---|---|
| Also known as | HDV-L |
| Sponsor | Diasome Pharmaceuticlas, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec (PHASE2)
- Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes (PHASE1)
- Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec (PHASE2)
- 21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus (PHASE2)
- Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) (PHASE2)
- Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDV-Lispro CI brief — competitive landscape report
- HDV-Lispro updates RSS · CI watch RSS
- Diasome Pharmaceuticlas, Inc. portfolio CI